Intensity Therapeutics announced promising phase 2 trial results for INT230-6 in early-stage triple-negative breast cancer (TNBC). In the INVINCIBLE-4 study, 71% of patients receiving INT230-6 plus standard immunochemotherapy achieved pathological complete response (pCR), meaning no invasive cancer was detected in breast or lymph nodes. This is significant as pCR is linked to lower recurrence risk. The treatment showed manageable side effects and potential to improve outcomes in aggressive TNBC, with further studies ongoing.
The Intensity Therapeutics study on INT230-6 in triple-negative breast cancer provides context for health sector performance on Pluang. As of Oct 23, 2026 18:41 WIB, out of 150 priced health-sector US stocks, 31 rose and 112 fell. Among notable movers, Cogent Biosciences Inc. (COGT) traded at USD 30.85 with a 1-day change of -1.47% and a typical hold time of 8 days, while Novavax Inc (NVAX) was priced at USD 9.85, down 1.40%, with a typical hold time of 59 days and a Pluang order activity skewed 76% sell to 24% buy. BrightSpring Health Services Inc. (BTSG) stood at USD 60.01, down 1.40%, with a typical hold time of 14 days.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
